bioAffinity Technologies ... (BIAFW)
NASDAQ: BIAFW
· Real-Time Price · USD
0.17
-0.00 (-0.64%)
At close: Apr 25, 2025, 10:43 AM
0.17
0.00%
After-hours: Apr 25, 2025, 04:00 PM EDT
Company Description
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
bioAffinity Technologies Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Maria Zannes J.D. |
Contact Details
Address: No Address available No city data available, Delaware United States | |
| Website | http://www.bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAFW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W117 |
| ISIN Number | US09076W1172 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer & Director |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dallas J. Coleman | Vice President of sales |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Julie Anne Overton | Director of Communications |
| Steven Girgenti | Founder & Executive Chairman of the Board |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 05, 2025 | S-1/A | [Amend] Filing |
| May 02, 2025 | S-1 | Filing |
| Apr 29, 2025 | 10-K/A | [Amend] Annual Report |
| Apr 22, 2025 | 424B3 | Filing |
| Apr 15, 2025 | PRE 14A | Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 11, 2025 | S-1 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 8-K | Current Report |